HIV-1 Immunology and Vaccine Development

The global challenge posed by HIV-1 arises from its rapid genetic diversification, extensive glycan shielding of the envelope glycoprotein and its ability to establish latent reservoirs. Immunological control centres on coordinated innate and adaptive responses. Natural killer cells and dendritic cells shape early responses, while CD4+ T helper cells orchestrate antibody and cytotoxic CD8+ T-cell development. Humoral responses can generate broadly neutralising antibodies (bnAbs) that target conserved Env epitopes, although these typically arise only after years of infection and extensive B-cell maturation. Vaccine design efforts seek to mimic natural bnAb evolution by presenting stabilised Env trimers, engineered to expose vulnerable sites while occluding decoy surfaces. Strategies include mosaic antigen sequences to address viral diversity, germline-targeting immunogens to prime bnAb precursors and sequential boosting to steer affinity maturation. Preclinical studies in nonhuman primates and early-phase human trials have demonstrated safety and immunogenicity, but durable protection remains elusive. An effective vaccine will likely need to integrate multivalent Env constructs, potent adjuvants and prime-boost regimens to induce both bnAbs and T-cell memory capable of preventing acquisition and containing viral reservoirs.

Research from Nature Portfolio

Recent structural studies using cryo-electron tomography have revealed that native HIV-1 Env trimers engage one, two or three CD4 molecules in an asymmetric sequence at membrane interfaces. These observations identify discrete intermediate states during virus attachment and membrane juxtaposition, demonstrating that Env–CD4 clusters organise into ring-like assemblies prior to full trimer opening. The dependence of clustering on capsid maturation suggests a mechanistic link between post-fusion core rearrangements and initial receptor engagement. Insights into asymmetric binding pathways inform immunogen design by highlighting transient conformations that may elicit neutralising responses against early entry intermediates.

HIV-1 Immunology and Vaccine Development publication trend

The graph below shows the total number of articles in hiv-1 immunology and vaccine development across all publications each year (not limited to Nature Index journals).

Technical terms

HIV-1 Env glycoprotein: The trimeric surface spike that mediates viral entry by engaging CD4 and co‐receptors on host cells.

Broadly neutralising antibodies: Antibodies capable of neutralising diverse HIV-1 strains by targeting conserved epitopes on Env.

Germline-targeting immunogen: A vaccine component engineered to engage naive B cells bearing unmutated precursor receptors of broadly neutralising antibodies.

Mosaic vaccine regimen: A strategy combining multiple variant antigens to broaden immune coverage against diverse viral sequences.

Tier 2 neutralisation: A classification of HIV-1 isolates that are moderately resistant to serum neutralisation, representative of circulating strains.

References

1. HIV-1 Env trimers asymmetrically engage CD4 receptors in membranes. Nature (2023).
2. Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial. The Lancet Infectious Diseases (2024).
3. HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity (2016).
4. Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches. Immunity (2017).